Skip to content

Cannabis stocks spike on U.S. legalization plans, strong forecasts

Cannabis stocks spike on U.S. legalization, strong forecasts

North American cannabis index, which tracks U.S. and Canadian cannabis companies, hit eighteen months high as democratic senators plan to pass legislation to end the federal ban on marijuana.

Shares of the only large capped weed company, Canopy Growth (NYSE: CGC), rallied more than 7% on Wednesday, extending year-to-date gains to 82%.

GW Pharmaceuticals’ (NASDAQ: GWPH) stock price soared more than 44% on Wednesday after Jazz Pharmaceuticals (NASDAQ: JAZZ) announced to acquire the medical marijuana company for $7.2 billion in cash and stock.

Shares of Canadian cannabis firm Aphria Inc (NASDAQ: APHA) soared more than 130% year to date amid speculations about the merger with Tilray, Inc. (NASDAQ: TLRY).

Investors are also showing confidence in Aurora Cannabis (NYSE: ACB); the price per ACB share surged by 29.04% from $10.19 to $13.15 over the last 30 days.

Cannabis stocks rally also gained momentum on expectations for increased institutional investments and strong growth forecasts for the upcoming years.

North American Marijuana Index. Source: Marijuanaindex.com

The government backing and positive forecasts adding to upside momentum

“Over the next six months, there’s an expectation of more capital coming into the industry because it will now be investable to institutional players, and institutional bankers will help bring more capital into the industry,” Tim Seymour, the founder, and chief investment officer of Seymour Asset Management, said.

The sharp cannabis stock momentum is also backed by double-digit growth expectations.

Cannabis sales in North America reached $18.1 billion in 2020, with expectations that sales will increase around 76% in the next five years to reach $39.1 billion levels by 2025, according to a recent Prohibition Partners report.

North American cannabis forecast/ Prohibition Partners

The government backing is the major catalysts for sales growth in the years ahead. Three senators, including Senate majority leader Chuck Schumer, said they would present “a unified discussion draft on comprehensive reform” in the coming months, and the passing of that bill will be a priority for the senate.

What’s more, American people also like to see cannabis legalization as Gallup poll in November hinted that 68% of Americans supported marijuana legalization.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Read Next:

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account?

Services

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.